Arcutis Biotherapeutics, Inc.
ARQT
株式のランク
#3994
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
株価
$32.74
時価総額
$4.12B
変化（1日）
2.68%
変化（1年）
56.82%
国
US
取引 Arcutis Biotherapeutics, Inc. (ARQT)
カテゴリー
Healthcare
Arcutis Biotherapeutics, Inc.（ARQT）の発行済株式数
June 2026 時点の発行済株式数 130.52M
Arcutis Biotherapeutics, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 130.52M です。December 2023 の終わりには、同社は 69.31M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Arcutis Biotherapeutics, Inc.（ARQT）の発行済株式数の履歴（2017 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 130.52M | 7.91% |
| 2024 | 120.96M | 74.53% |
| 2023 | 69.31M | 25.94% |
| 2022 | 55.03M | 11.39% |
| 2021 | 49.41M | 38.52% |
| 2020 | 35.67M | -6.36% |
| 2019 | 38.09M | 5.11% |
| 2018 | 36.24M | 3,331.44% |
| 2017 | 1.06M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 94.53% |
US
|
|
| 396.00M | 203.40% |
US
|
|
| 478.91M | 266.92% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.36% |
NL
|
